We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

128 hedge funds and large institutions have $335M invested in Progenics Pharmaceuticals Inc in 2019 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 35

2% less capital invested

Capital invested by funds: $343M → $335M (-$8.12M)

5% less funds holding

Funds holding: 135 → 128 (-7)

27% less call options, than puts

Call options by funds: $1.01M | Put options by funds: $1.38M

28% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 25

Holders
128
Holders Change
-7
Holders Change %
-5.19%
% of All Funds
2.52%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
18
Increased
44
Reduced
35
Closed
25
Calls
$1.01M
Puts
$1.38M
Net Calls
-$367K
Net Calls Change
-$1.64M

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$7.81M
2
AA
AQR Arbitrage
Connecticut
+$5.59M
3
FCM
Farallon Capital Management
California
+$4.76M
4
State Street
State Street
Massachusetts
+$3.86M
5
BlackRock
BlackRock
New York
+$3M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$14.1M
2
RHJA
Rice Hall James & Associates
California
-$8.98M
3
PA
Pinnacle Associates
New York
-$6.43M
4
PFC
Phocas Financial Corp
California
-$5.17M
5
RA
Royce & Associates
New York
-$4.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
101
LPL Financial
California
$52K -$2.16K -408 -4%
AIP
102
Ameritas Investment Partners
Nebraska
$38K +$7.35K +1,390 +23%
DSC
103
Duncker Streett & Co
Missouri
$33K +$34.4K +6,500 New
PNC Financial Services Group
104
PNC Financial Services Group
Pennsylvania
$26K +$15.6K +2,944 +156%
Zurich Cantonal Bank
105
Zurich Cantonal Bank
Switzerland
$24K – – –
Rockefeller Capital Management
106
Rockefeller Capital Management
New York
$18K +$19K +3,591 New
MOACM
107
Mutual of America Capital Management
New York
$16K -$582 -110 -3%
AG
108
Advisor Group
Arizona
$15K -$15.8K -2,982 -51%
Royal Bank of Canada
109
Royal Bank of Canada
Ontario, Canada
$15K +$12K +2,276 +241%
PCM
110
Prelude Capital Management
New York
$15K +$12.9K +2,448 +453%
LIA
111
LS Investment Advisors
Michigan
$12K – – –
Federated Hermes
112
Federated Hermes
Pennsylvania
$9K -$598 -113 -6%
SPIA
113
Steward Partners Investment Advisory
New York
$7K – – –
TFS
114
TrustCore Financial Services
Tennessee
$5K – – –
ASN
115
Advisory Services Network
Georgia
$3K – – –
Daiwa Securities Group
116
Daiwa Securities Group
Japan
$3K – – –
WT
117
Whittier Trust
California
$3K – – –
IA
118
IFP Advisors
Florida
$2K – – –
SF
119
Synovus Financial
Georgia
$2K – – –
US Bancorp
120
US Bancorp
Minnesota
$2K – – –
LTFS
121
Ladenburg Thalmann Financial Services
Florida
$1K -$7.82K -1,478 -83%
CAW
122
Cornerstone Advisors (Washington)
Washington
$1K – – –
FRA
123
Front Row Advisors
California
$1K – – –
GAM
124
Gemmer Asset Management
California
$1K – – –
IFAM
125
Institutional & Family Asset Management
Colorado
$1K – – –
3 4
5
6 7

PGNX Hedge Fund Activity: Q4 2019 in Review

128 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2019, worth a combined $335M — down 2.4% from $343M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of PGNX and 18 opened new positions — a net loss of 7 holders — while 35 trimmed existing stakes and 44 added.

The largest buyer was Broadfin Capital, adding an estimated $7.81M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $14.1M sold.

  • 128 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2019, down from 135 in Q3 2019.
  • Funds reported $335M of Progenics Pharmaceuticals Inc stock for Q4 2019, down 2.4% quarter-over-quarter.
  • 18 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2019 and 25 closed out, a net change of -7 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q4 2019 was Broadfin Capital, an estimated $7.81M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q4 2019 was Point72 Asset Management, an estimated $14.1M sold.

Based on aggregated 13F filings for Q4 2019.